MorphoSys and Vivoryon Therapeutics Enter Agreement in Immuno-Oncology

10-Jul-2019 - MorphoSys AG and Vivoryon Therapeutics AG announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon's small molecule QPCTL inhibitors in the field of oncology. The option covers worldwide development and ...

MorphoSys Appoints Jean-Paul Kress as New CEO

25-Jun-2019 - MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effect on September 1, 2019. Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a strong ...

MorphoSys received a milestone payment from Janssen

Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis

17-Apr-2019 - MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract. Janssen has initiated a phase 1b proof-of-concept clinical ...

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

17-Sep-2018 - Galapagos NV and MorphoSys AG announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, ...

Dr. Malte Peters to become new Chief Development Officer of MorphoSys AG

05-Jan-2017 - The Supervisory Board of MorphoSys AG has appointed Dr. Malte Peters as Chief Development Officer. Dr. Peters will take up the position on March 1, 2017 and will succeed Dr. Arndt Schottelius, who is leaving to pursue other opportunities. Dr. Peters joins MorphoSys from Sandoz, where he serves as ...

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody

21-Oct-2016 - MorphoSys AG announced that it has received a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial with a novel HuCAL antibody. The antibody will be tested in the field of cancer. Financial details were not disclosed. "This is the 13th therapeutic antibody ...

Lanthio Pharma expands management team

20-Sep-2016 - The Dutch biopharmaceutical company Lanthio Pharma B.V., a wholly owned subsidiary of MorphoSys AG, announced the appointment of Axel Mescheder, M.D. as Chief Medical Officer (CMO). Dr. Heinz Schwer, Chief Executive Officer of Lanthio Pharma, commented: "We are very pleased to welcome Axel ...

MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement

06-Apr-2016 - MorphoSys AG announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular ...

MorphoSys and G7 Therapeutics Sign Alliance to Develop Antibody Therapeutics

Collaboration Broadens MorphoSys' Capabilities to Target Novel Antigen Classes

06-Aug-2015 - MorphoSys AG and G7 Therapeutics AG announced that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins such as ion channels. Under the terms of the agreement, G7 ...

Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target

31-Jul-2015 - MorphoSys AG announced that its partner Heptares Therapeutics, a wholly owned subsidiary of Sosei Group Corporation, has exercised an option to initiate a therapeutic antibody program arising from the alliance the companies entered into in February 2013. The program will leverage MorphoSys’s ...